Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) confirmed on Wednesday that it plans to continue the development of efgartigimod to Phase 3 in adults with primary Sjogren's disease (SjD).
This decision follows an analysis of topline data from the Phase 2 RHO study which showed favourable safety, efficacy and biomarker results, confirming the therapeutic potential of efgartigimod.
With primary Sjogren's disease lacking FDA-approved treatments, efgartigimod offers promise as a potential alternative therapy for patients.
Sjogren's disease, characterised by immune-mediated destruction of exocrine glands, predominantly affects women. Common symptoms include dry eyes and mouth, fatigue, joint point and impaired cognitive function, and a substantial subset of patients suffer from extraglandular systemic disease.
Designed to target disease-causing immunoglobulin G antibodies, efgartigimod has demonstrated clinical efficacy across multiple endpoints.
Pierre Fabre Pharmaceuticals reports FDA acceptance and Priority Review of Tabelecleucel BLA
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Hyperfine secures FDA clearance for faster brain imaging software
Silo Pharma agrees Alzheimer's drug licence
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Camurus reports positive Phase 3 ACROINNOVA 2 results
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI